Allakos Inc is a clinical-stage biotechnology company developing therapeutic antibodies targeting a broad range of allergic, inflammatory, and proliferative diseases
Allakos Inc is a clinical-stage biotechnology company developing therapeutic antibodies targeting a broad range of allergic, inflammatory, and proliferative diseases. The Company’s lead antibody, AK002, targets Siglec-8, an inhibitory receptor on human mast cells and eosinophils.